Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Rating of “Moderate Buy” from Brokerages

Posted by Brian Himes on Jun 14th, 2026

Theravance Biopharma, Inc. (NASDAQ:TBPH – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the company, MarketBeat reports. Five investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $21.8333.

Several equities research analysts recently weighed in on TBPH shares. Oppenheimer downgraded shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a report on Thursday, March 5th. TD Cowen upped their price objective on shares of Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, March 23rd. BTIG Research reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Theravance Biopharma in a report on Friday, March 20th. B. Riley Financial upped their price objective on shares of Theravance Biopharma from $14.00 to $17.00 and gave the stock a “neutral” rating in a report on Tuesday, April 7th. Finally, Wall Street Zen downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, May 16th.

View Our Latest Stock Report on Theravance Biopharma

Insiders Place Their Bets

In related news, SVP Rhonda Farnum sold 31,067 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the completion of the sale, the senior vice president owned 232,699 shares of the company’s stock, valued at $3,248,478.04. This represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 7.65% of the stock is owned by insiders.

Institutional Investors Weigh In On Theravance Biopharma

Institutional investors have recently bought and sold shares of the stock. Quarry LP acquired a new stake in Theravance Biopharma in the third quarter worth about $26,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Theravance Biopharma by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 515 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in Theravance Biopharma by 107.4% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 1,411 shares during the period. CIBC Private Wealth Group LLC raised its position in Theravance Biopharma by 20,269.6% in the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 4,662 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its position in Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 781 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Stock Performance

Shares of TBPH opened at $16.64 on Friday. Theravance Biopharma has a 1 year low of $10.42 and a 1 year high of $21.03. The company has a market cap of $857.84 million, a price-to-earnings ratio of 7.56 and a beta of 0.17. The firm has a fifty day moving average of $16.46 and a 200-day moving average of $17.47.

Theravance Biopharma (NASDAQ:TBPH – Get Free Report) last announced its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. The firm had revenue of $17.70 million for the quarter. Analysts predict that Theravance Biopharma will post 1.54 EPS for the current year.

Theravance Biopharma Company Profile

(Get Free Report)

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.